TABLE 2.
In vitro activity against Gram-positive organisms
| Organism name or group | No. of isolates | Antibiotica | MIC range (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) |
|---|---|---|---|---|---|
| S. aureus | 55 | Omadacycline | ≤0.06–1 | 0.125 | 0.5 |
| Tetracycline | ≤0.06–64 | 0.125 | 64 | ||
| Minocycline | ≤0.06–16 | 0.125 | 8 | ||
| Cefotaxime | 1–>64 | 32 | >64 | ||
| Vancomycin | 0.25–2 | 0.5 | 1 | ||
| Levofloxacin | ≤0.06–>64 | 4 | 32 | ||
| Linezolid | 0.5–2 | 2 | 2 | ||
| Azithromycin | 0.25–>64 | >64 | >64 | ||
| Clindamycin | ≤0.06–>64 | 0.125 | >64 | ||
| Doxycycline | ≤0.06–8 | ≤0.06 | 8 | ||
| Methicillin-resistant S. aureus | 39 | Omadacycline | 0.125–1 | 0.25 | 0.5 |
| Tetracycline | ≤0.06–64 | 0.25 | 64 | ||
| Minocycline | ≤0.06–16 | 0.25 | 8 | ||
| Cefotaxime | 4–>64 | >64 | >64 | ||
| Vancomycin | 0.25–2 | 0.5 | 1 | ||
| Levofloxacin | 0.5–>64 | 8 | 32 | ||
| Linezolid | 0.5–2 | 2 | 2 | ||
| Azithromycin | 0.5–>64 | >64 | >64 | ||
| Clindamycin | ≤0.06–>64 | >64 | >64 | ||
| Doxycycline | ≤0.06–8 | 0.125 | 8 | ||
| Methicillin-sensitive S. aureus | 16 | Omadacycline | ≤0.06–0.25 | 0.125 | 0.125 |
| Tetracycline | ≤0.06–16 | ≤0.06 | 0.125 | ||
| Minocycline | ≤0.06–0.125 | ≤0.06 | 0.125 | ||
| Cefotaxime | 1–2 | 2 | 2 | ||
| Vancomycin | 0.25–0.5 | 0.5 | 0.5 | ||
| Levofloxacin | ≤0.06–4 | 0.125 | 0.125 | ||
| Linezolid | 1–2 | 1 | 2 | ||
| Azithromycin | 0.25–32 | 0.5 | 0.5 | ||
| Clindamycin | ≤0.06–0.125 | ≤0.06 | 0.125 | ||
| Doxycycline | ≤0.06–1 | ≤0.06 | ≤0.06 | ||
| Multidrug- and methicillin-resistant S. aureus | 10 | Omadacycline | 0.25–0.5 | 0.5 | 0.5 |
| Tetracycline | 32–>64 | >64 | >64 | ||
| Minocycline | 2–16 | 8 | 8 | ||
| Cefotaxime | 32–64 | >64 | >64 | ||
| Vancomycin | 0.5–1 | 1 | 1 | ||
| Levofloxacin | 8–32 | 8 | 32 | ||
| Linezolid | 0.5–2 | 1 | 2 | ||
| Azithromycin | >64 | >64 | >64 | ||
| Clindamycin | >64 | >64 | >64 | ||
| Doxycycline | 2–8 | 8 | 8 | ||
| E. faecalis | 31 | Omadacycline | 0.125–0.5 | 0.25 | 0.5 |
| Tetracycline | 0.125–>64 | 32 | 64 | ||
| Minocycline | 0.125–16 | 8 | 16 | ||
| Vancomycin | 0.5–8 | 1 | 2 | ||
| Levofloxacin | 0.5–64 | 1 | 32 | ||
| Linezolid | 1–4 | 1 | 2 | ||
| Azithromycin | 1–>64 | 8 | >64 | ||
| Clindamycin | 2–>64 | 32 | >64 | ||
| Doxycycline | ≤0.06–16 | 4 | 16 | ||
| Multidrug-resistant E. faecalis | 3 | Omadacycline | 0.25–0.5 | 0.25 | 0.5 |
| Tetracycline | 32–64 | 32 | 64 | ||
| Minocycline | 8–16 | 8 | 16 | ||
| Vancomycin | 0.5–8 | 0.5 | 8 | ||
| Levofloxacin | 16–64 | 32 | 64 | ||
| Linezolid | 1 | 1 | 1 | ||
| Azithromycin | >64 | >64 | >64 | ||
| Clindamycin | >64 | >64 | >64 | ||
| Doxycycline | 4 | 4 | 4 | ||
| E. faecium | 24 | Omadacycline | 0.125–0.5 | 0.25 | 0.5 |
| Tetracycline | 0.125–>64 | 32 | 64 | ||
| Minocycline | 0.125–32 | 8 | 16 | ||
| Vancomycin | 0.5–>64 | >64 | >64 | ||
| Levofloxacin | 1–>64 | 64 | >64 | ||
| Linezolid | 0.5–4 | 2 | 2 | ||
| Azithromycin | 4–>64 | >64 | >64 | ||
| Clindamycin | ≤0.06–>64 | >64 | >64 | ||
| Doxycycline | ≤0.06–16 | 2 | 8 | ||
| Vancomycin-resistant E. faecium | 19 | Omadacycline | 0.125–0.5 | 0.25 | 0.5 |
| Tetracycline | 0.125–>64 | 32 | 64 | ||
| Minocycline | 0.25–32 | 8 | 16 | ||
| Vancomycin | 64–>64 | >64 | >64 | ||
| Levofloxacin | 1–>64 | 64 | >64 | ||
| Linezolid | 0.5–4 | 2 | 2 | ||
| Azithromycin | >64 | >64 | >64 | ||
| Clindamycin | >64 | >64 | >64 | ||
| Doxycycline | ≤0.06–8 | 2 | 4 | ||
| Multidrug- and vancomycin-resistant E. faecium | 12 | Omadacycline | 0.125–0.5 | 0.25 | 0.5 |
| Tetracycline | 32–>64 | 32 | >64 | ||
| Minocycline | 4–16 | 8 | 16 | ||
| Vancomycin | >64 | >64 | >64 | ||
| Levofloxacin | 8–>64 | 32 | >64 | ||
| Linezolid | 0.5–2 | 1 | 2 | ||
| Azithromycin | >64 | >64 | >64 | ||
| Clindamycin | >64 | >64 | >64 | ||
| Doxycycline | 2–8 | 2 | 4 | ||
| S. pneumoniae | 41 | Omadacycline | ≤0.06–0.25 | ≤0.06 | 0.125 |
| Tetracycline | ≤0.06–64 | 16 | 32 | ||
| Minocycline | ≤0.06–8 | 2 | 8 | ||
| Cefotaxime | ≤0.06–8 | 1 | 2 | ||
| Vancomycin | ≤0.06–0.5 | 0.25 | 0.25 | ||
| Levofloxacin | 0.25–1 | 0.5 | 1 | ||
| Penicillin | ≤0.06–8 | 2 | 4 | ||
| Linezolid | 0.25–2 | 1 | 1 | ||
| Azithromycin | ≤0.06–>64 | 2 | >64 | ||
| Clindamycin | ≤0.06–>64 | ≤0.06 | >64 | ||
| Doxycycline | ≤0.06–4 | 2 | 4 | ||
| Penicillin-resistant S. pneumoniae | 23 | Omadacycline | ≤0.06 | ≤0.06 | ≤0.06 |
| Tetracycline | ≤0.06–64 | 32 | 32 | ||
| Minocycline | 0.125–8 | 8 | 8 | ||
| Cefotaxime | 0.5–8 | 1 | 8 | ||
| Vancomycin | 0.125–0.25 | 0.25 | 0.25 | ||
| Levofloxacin | 0.5–1 | 0.5 | 1 | ||
| Penicillin | 2–8 | 4 | 8 | ||
| Linezolid | 0.5–2 | 1 | 1 | ||
| Azithromycin | ≤0.06–>64 | 4 | >64 | ||
| Clindamycin | ≤0.06–>64 | ≤0.06 | >64 | ||
| Doxycycline | ≤0.06–4 | 4 | 4 | ||
| Multidrug- and penicillin-resistant S. pneumoniae | 18 | Omadacycline | ≤0.06 | ≤0.06 | ≤0.06 |
| Tetracycline | 16–64 | 32 | 32 | ||
| Minocycline | 4–8 | 8 | 8 | ||
| Cefotaxime | 0.5–8 | 1 | 8 | ||
| Vancomycin | 0.125–0.25 | 0.125 | 0.25 | ||
| Levofloxacin | 0.5–1 | 0.5 | 1 | ||
| Penicillin | 2–8 | 4 | 8 | ||
| Linezolid | 0.5–1 | 1 | 1 | ||
| Azithromycin | 2–>64 | >64 | >64 | ||
| Clindamycin | ≤0.06–>64 | >64 | >64 | ||
| Doxycycline | 2–4 | 4 | 4 | ||
| S. pyogenes | 30 | Omadacycline | ≤0.06–0.5 | 0.125 | 0.25 |
| Tetracycline | ≤0.06–64 | ≤0.06 | 64 | ||
| Minocycline | 0.125–8 | 0.25 | 8 | ||
| Cefotaxime | ≤0.06 | ≤0.06 | ≤0.06 | ||
| Vancomycin | 0.25 | 0.25 | 0.25 | ||
| Levofloxacin | 0.25–1 | 0.25 | 1 | ||
| Linezolid | 0.5–1 | 1 | 1 | ||
| Azithromycin | ≤0.06–>64 | ≤0.06 | 8 | ||
| Clindamycin | ≤0.06–>64 | ≤0.06 | ≤0.06 | ||
| Doxycycline | ≤0.06–8 | ≤0.06 | 8 | ||
| S. agalactiae | 18 | Omadacycline | ≤0.06–0.25 | 0.125 | 0.125 |
| Tetracycline | ≤0.06–64 | 32 | 64 | ||
| Minocycline | 0.125–32 | 16 | 16 | ||
| Cefotaxime | ≤0.06 | ≤0.06 | ≤0.06 | ||
| Vancomycin | 0.125–0.5 | 0.25 | 0.5 | ||
| Levofloxacin | 0.125–0.5 | 0.5 | 0.5 | ||
| Linezolid | 1–1 | 1 | 1 | ||
| Azithromycin | ≤0.06–8 | ≤0.06 | 0.125 | ||
| Clindamycin | ≤0.06 | ≤0.06 | ≤0.06 | ||
| Doxycycline | ≤0.06–16 | 8 | 8 |
a
Commercial-grade tigecycline was not available at the time of in vitro testing.